Atamax® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children from 6 years of age, in adolescents and in adults as part of a complete treatment program. Treatment should be initiated by a specialist in the treatment of ADHD, such as paediatricians, child psychiatrists or psychiatrists. Diagnosis should be made according to current DSM criteria or guidelines included in the ICD.
In adults, the presence of ADHD symptoms already existing in childhood should be confirmed. It would be desirable for them to be corroborated by a third party and treatment with Atamax should not be started when the verification of symptoms of ADHD in childhood is doubtful. A diagnosis cannot be made based solely on the presence of one or more symptoms of ADHD. Patients should have ADHD of at least moderate severity based on clinical judgment, demonstrated by at least moderate functional impairment in 2 or more domains (eg, social, academic, and/or job performance), affecting multiple aspects of the patient’s life.
Additional information for the safe use of this medication: A comprehensive treatment program usually includes psychological, educational, and social measures and is intended to stabilize patients with a behavioral syndrome characterized by symptoms that may include chronic attention deficit disorder, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs, and abnormal EEG. Learning may or may not be affected.
Pharmacological treatment is not indicated for all patients with this syndrome and the decision to use the drug should be based on an in-depth evaluation of the severity of the patient’s symptoms and disorder, in relation to their age and the persistence of the symptoms.
Download sheet
